Wells Fargo Starts Calithera Biosciences (CALA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CALA Hot Sheet
Price: $0.00 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Wells Fargo initiated coverage on Calithera Biosciences (NASDAQ: CALA) with an Outperform rating and a price target of $19-$20.
For an analyst ratings summary and ratings history on Calithera Biosciences click here. For more ratings news on Calithera Biosciences click here.
Shares of Calithera Biosciences closed at $11.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Starts Yamazaki Baking Co Ltd (2212:JP) at Buy
- Roth/MKM Starts Natera (NTRA) at Buy
- Needham Starts Diodes (DIOD) at Buy, 'Significant Margin Upside'
Create E-mail Alert Related Categories
New CoverageRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
